Cancer Immunoprevention Network

Official X account of the NCI Cancer Immunoprevention Network (CIP-Net)

[Cancer Immunoprevention Network @NCI_CIPNet]

The Cancer Immunoprevention Network (CIP-Net), established by the National Cancer Institute (NCI), advances the understanding of fundamental immunoprevention mechanisms, drives the discovery of novel strategies, and supports the preclinical development and testing of new interventions. More info: https://t.co/cB4HvgBEZw

[Cancer Immunoprevention Network @NCI_CIPNet]

Join the @theNCI Division of Cancer Prevention Immunology Interest Group for a special seminar presentation on Wednesday June 10 at 1pm ET. We will hear from Dr. Nicholas Arpaia @arpaialab, Associate Professor of Microbiology & Immunology at the @Columbia Herbert Irving Comprehensive Cancer Center discussing his research in: "Programmable Probiotics for Personalized Cancer Immunoprevention and Immunotherapy." Register today: https://t.co/PeBf9Pv6BK

#CancerResearch #CancerPrevention

[National Cancer Institute @theNCI]

⏲️Faster clinical trial activation means faster access to innovation. During today’s #ASCO26 panel, @NCIDirector discussed the importance of aligning stakeholders, supporting cancer centers with guidance and incentives, sharing best practices, and partnering across @HHSGov.

[Cancer Research Institute @CancerResearch]

Cancer Immunotherapy Month kicks off June 1! Join CRI for a monthlong celebration of the scientific breakthroughs, translational advances, and pioneering research continuing to push the immunotherapy field forward. #CancerResearch #Immunotherapy

[Cancer Immunoprevention Network @NCI_CIPNet]

Register now for the @theNCI Division of Cancer Prevention Early Career Scientist Spotlight Research Seminar Series. https://t.co/V7nWfBd681

[Nature Reviews Cancer @NatureRevCancer]

NEW content online! Regulation of immune checkpoint molecules in cancer immune evasion and therapy https://t.co/Akm5jtVmZd

[Cancer Cell @Cancer_Cell]

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors https://t.co/PfCqPwXSNu

[Nature Cancer @NatureCancer]

⭐Out today!

Read the phase I clinical trial on neoantigen DNA vaccine for patients with glioblastoma
https://t.co/sFBuppavXy

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors" https://t.co/XNGrn8jKeR
@AliceIndini

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

Join the conversation shaping the future of cancer care at the NCI workshop “Precision in Practice: A Functional Medicine Workshop” on July 1-2, 2026 at @theNCI Shady Grove Campus and online.
Day 1 will highlight the current state-of-the-art in functional precision medicine, featuring a keynote presentation by Dr. Anthony Letai @NCIDirector. Day 2 will focus on defining the key scientific questions that will shape the next decade of cancer care.
The workshop will bring together leaders from academia, industry, government, and patient advocacy to accelerate the translation of functional precision oncology into clinical practice.
Explore the draft agenda and register today:
https://t.co/YQEo8P1vDA

#CancerResearch #PrecisionMedicine #FunctionalPrecisionMedicine #Oncology #CancerCare

[Cancer Immunoprevention Network @NCI_CIPNet]

A curated list of NIH/NCI shared resources is now available on our web portal. Check it out: https://t.co/HZEYXLJ6UI

[Cancer Immunoprevention Network @NCI_CIPNet]

Great kickoff for the CIP-Net Resource Sharing WG today! 🚀
Many thanks to WG Chairs Dr. Anjana Bhardwaj of @UTMDAnderson and Dr. Henry Withers of @RoswellPark for leading a thoughtful discussion on building a collaborative framework for resource sharing across the network.
And thank you to all members for the active participation and valuable input. Looking forward to what we build together!
#CIPNet #CancerImmunoprevention #TeamScience

[Cancer Immunoprevention Network @NCI_CIPNet]

Community input needed!

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

We’re building a shared resource of free webinars on AI in cancer research, to support and empower our scientific community. 🧬🤖
If you know of any great sessions, please share the links in the comments and help grow this collective knowledge hub!

[Cancer Cell @Cancer_Cell]

Online Now: T cell extracellular vesicles go nuclear to turn cold tumors hot https://t.co/lpHj0GZIpx

[Acquired Resistance to Therapy Network (ARTNet) @NCIARTNet]

New review just out in Nature Reviews Drug Discovery:
Drs. Erik S. Knudsen, Agnieszka K. Witkiewicz, and Sheheryar Kabraji of @RoswellPark outline the evolving landscape of CDK inhibition: from the success of CDK4/6 inhibitors in breast cancer to next-gen strategies expanding into other tumor types.
From combination therapies (HER2, PI3K) to CDK2 targeting and biomarker-guided patient selection, this piece captures where the field is heading a decade after first FDA approvals.
#CancerResearch #CDK #BreastCancer #TargetedTherapy

[Science Magazine @ScienceMagazine]

In a new #ScienceReview, researchers discuss a variety of methods to reimagine human-centric drug development.

Learn more: https://t.co/PlVhqBWYwh

[Nature Biotechnology @NatureBiotech]

mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression https://t.co/HCQVKRQxJU

[Nature Cancer @NatureCancer]

📢Today we launch our Series on Tumor Heterogeneity and Plasticity featuring commissioned Reviews and a selection of articles published in Nature Cancer!
Read about EMT, CAF plasticity, immune cell plasticity, cellular neighborhoods and more here:
🔗https://t.co/XudgPd5Vax

[Nature Reviews Drug Discovery @NatRevDrugDisc]

For readers interested in the potential of in vivo CAR T therapies for cancer and autoimmune diseases, here's a comprehensive review
https://t.co/lBXbFGb0c2
https://t.co/VZojof75jl

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma" https://t.co/Gv6RGlxiLE